In a nutshell This study investigated the overall survival and clinical characteristics of metastatic (spread to other parts of the body) melanoma patients undergoing therapy with dabrafenib (Tafinlar) combined with trametinib (Mekinist). Researchers suggested that the combined treatment is associated with improved overall survival when compared to...
Read More
In a nutshell The authors aimed to analyze the factors that could predict resistance to BRAF inhibitor therapy in advanced melanoma. The authors found out that levels of certain proteins and the presence of a type of immune cell could predict the occurrence of resistance. Some background In advanced melanoma (stages 3 or 4), cancer spreads...
Read More
In a nutshell The authors evaluated the effectiveness of combination therapy in advanced melanoma patients with mutated (permanent changes) BRAF genes. Some background In advanced melanoma (stage III/ IV), cancer spreads from the skin to other parts of the body. Targeted therapy has been shown to improve patient outcomes in the advanced...
Read More
In a nutshell The authors reviewed current and future treatment options for melanoma patients with mutations (permanent changes) in various genes. Some background In 40-60% of skin melanoma patients, BRAF genes are mutated. These genes are involved in cellular signaling and important protein function. These proteins are...
Read More
In a nutshell This article published in 2013 reviews information from clinical studies which looked at new treatments for cutaneous melanoma. These include drugs that aim to stimulate the body's anti-tumor immune response, such as ipilimumab (Yervoy) and tremelimumab and those that target genetic mutations in cancer cells. Some background...
Read More
